Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dice Thinks It Holds An Ace With Oral IL-17 Inhibitor In Psoriasis

Executive Summary

The company believes it has a potential best-in-class oral drug for psoriasis in development following positive first-in-human clinical trial data. A larger Phase II study is needed.

You may also be interested in...



BMS Aims To Unseat Otezla In Psoriasis With US FDA-Approved Sotyktu

Chief commercialization officer Chris Boerner said BMS plans to replace Otezla as the oral standard of care for moderate-to-severe psoriasis with Sotyktu (deucravacitinib); its list price is about 40% higher than Amgen’s product.

Sanofi Partnership On Oral IL-17 Could Be Turning Point For C4XD

The UK drug discovery specialist has made slow progress until now, but the Sanofi deal could yield a challenger in the competitive psoriasis field.

Astellas Plots US Portfolio Expansion

US president Mark Reisenauer talked to Scrip about the company's next growth drivers, including fezolinetant for vasomotor symptoms and zolbetuximab for gastric cancer.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC147187

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel